Version 1
: Received: 25 July 2018 / Approved: 25 July 2018 / Online: 25 July 2018 (09:59:26 CEST)
How to cite:
Bucheit, L.; Johansen Taber, K.; Ready, K. Validation of a Digital Identification Tool for Individuals at Risk for Hereditary Cancer Syndromes. Preprints2018, 2018070476. https://doi.org/10.20944/preprints201807.0476.v1
Bucheit, L.; Johansen Taber, K.; Ready, K. Validation of a Digital Identification Tool for Individuals at Risk for Hereditary Cancer Syndromes. Preprints 2018, 2018070476. https://doi.org/10.20944/preprints201807.0476.v1
Bucheit, L.; Johansen Taber, K.; Ready, K. Validation of a Digital Identification Tool for Individuals at Risk for Hereditary Cancer Syndromes. Preprints2018, 2018070476. https://doi.org/10.20944/preprints201807.0476.v1
APA Style
Bucheit, L., Johansen Taber, K., & Ready, K. (2018). Validation of a Digital Identification Tool for Individuals at Risk for Hereditary Cancer Syndromes. Preprints. https://doi.org/10.20944/preprints201807.0476.v1
Chicago/Turabian Style
Bucheit, L., Katherine Johansen Taber and Kaylene Ready. 2018 "Validation of a Digital Identification Tool for Individuals at Risk for Hereditary Cancer Syndromes" Preprints. https://doi.org/10.20944/preprints201807.0476.v1
Abstract
The number of individuals meeting criteria for genetic counseling and testing for hereditary cancer syndromes (HCS) is far less than the number that actually receive it. To facilitate identification of patients at risk for HCS, Counsyl developed a digital identification tool (digital ID tool) to match personal and family cancer history to National Comprehensive Cancer Network (NCCN) BRCA-related Hereditary Breast and Ovarian Cancer (HBOC), Lynch syndrome, and polyposis testing criteria in one-to-one, automated fashion. The purpose of this study was to validate the ability of the digital ID tool to accurately identify histories that do and do not meet NCCN testing criteria. Methods: Third-party recorded three-generation pedigrees were retrospectively reviewed by a certified genetic counselor (CGC) to determine if independent events included in pedigree histories met NCCN guidelines, and were then sorted into groups: high risk events (meets criteria) and low risk events (does not meet criteria). Events were entered into the digital ID tool to determine the extent of its concordance with events sorted by CGC review. Statistical tests of accuracy were calculated at a 95% confidence interval (CI). Results: 197 pedigrees were reviewed consecutively representing 765 independent events for analysis across groups. 382/382 (100%) high risk events identified by the digital ID tool and 381/383 (99.47%) low risk events identified by the digital ID tool were concordant with CGC sorting. The digital ID tool had a sensitivity of 100% (99.04-100% CI) and specificity of 99.48% (98.13-99.94% CI). The overall accuracy of the digital ID tool was estimated to be 99.74% (99.06-99.97% CI), reflecting the rate at which the digital ID tool reached the same conclusion as that of CGC review of pedigree events for the recommendation of genetic testing for individuals at risk for HCS. Conclusions: The digital ID tool accurately matches NCCN criteria in one-to-one fashion to identify at-risk individuals for HCS and may be useful in clinical practice, specifically for BRCA-related HBOC and Lynch Syndrome.
Keywords
BRCA1, BRCA2, Hereditary Breast and Ovarian Cancer, Lynch Syndrome, Hereditary cancer, Family history screening. Risk assessment, Digital tool, Health information technology
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
